Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Collaboration revenue from Sanofi increased 22% to $1.21 billion in the fourth quarter, while Bayer collaboration revenue was flat at $377 million. Notably, revenue from cancer drug Libtayo ...

driven by increased demand for Eylea HD (aflibercept 8 mg), Libtayo (cemiplimab), its key medication in the oncology franchise, as well as revenue growth from its collaboration with Sanofi (SNY ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi SNY for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat ...